Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Enliven Therapeutics, Inc. (ELVN) had Return on Tangible Equity of -6.46% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-29.67M |
|
-- |
|
-- |
|
$34.28M |
|
$-34.28M |
|
$4.62M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-29.67M |
|
$-34.28M |
|
$-34.18M |
|
56.66M |
|
56.66M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$474.88M |
|
$0.03M |
|
$1.29M |
|
$476.17M |
|
$16.57M |
|
-- |
|
-- |
|
$16.57M |
|
$459.60M |
|
$459.60M |
|
$459.60M |
|
59.44M |
|
| Cash Flow Statement Financials | |
$-70.30M |
|
$-173.84M |
|
$218.87M |
|
$124.17M |
|
$98.90M |
|
$-25.27M |
|
$34.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
28.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-70.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.46% |
|
|
Return on Tangible Equity |
-6.46% |
-6.23% |
|
-6.46% |
|
$7.73 |
|
$-1.24 |
|
$-1.24 |
|